Reporting owner · CIK 0002050167

Dandekar Atul

Visual SEC Form 4 history across 1 companies, 3 transactions and 1 filings.

CSBOCSBOMaze Therapeutics, Inc.
Open-market mix
Filings1Form 4 records
Buying$00 purchases
Selling$206.8K1 sales
Net value−$206.8KBuys minus sells
Companies12 securities
Most recentAug 28, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-51Aug 26

Net value flow

Buys minus sells

Aug 26
−$206.8K

Transaction texture

Ownership and ticket size

Average P/S size$206.8K
Median P/S size$206.8K
Direct3
Indirect0
Aug 28, 2026exercise

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Maze Therapeutics, Inc. on Aug 28, 2026 valued at $206,824.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Maze Therapeutics, Inc. on Aug 28, 2026 valued at $206,824.

Review SEC filing

Associated companies

Visual map of known reporting history

TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
MAZEDandekar Atul
CSBO
exercise10b5-17.50k$0M0.0%08/3108/28
MAZEDandekar Atul
CSBO
sale10b5-17.50k-$20.6MS0.0%08/3108/28
MAZEDandekar Atul
CSBO
exercise10b5-17.50k$7.81MM0.0%08/3108/28

Dandekar Atul Insider Activity FAQ

SEC Form 4 context

Who is Dandekar Atul?

Dandekar Atul is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002050167.

Which companies has Dandekar Atul reported transactions for?

Maze Therapeutics, Inc.

When was Dandekar Atul's latest insider buy?

No open-market insider purchase is available for this period.

When was Dandekar Atul's latest insider sale?

sale at Maze Therapeutics, Inc. on Aug 28, 2026 valued at $206,824.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.